- Home
- NTGR vs MLYS Comparison
NTGR vs MLYS Comparison
Compare NTGR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTGR
- MLYS
- Stock Information
- Founded
- NTGR 1996
- MLYS 2019
- Country
- NTGR United States
- MLYS United States
- Employees
- NTGR N/A
- MLYS N/A
- Industry
- NTGR Telecommunications Equipment
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- NTGR Utilities
- MLYS Health Care
- Exchange
- NTGR Nasdaq
- MLYS Nasdaq
- Market Cap
- NTGR 567.8M
- MLYS 609.7M
- IPO Year
- NTGR N/A
- MLYS 2023
- Fundamental
- Price
- NTGR $29.54
- MLYS $11.87
- Analyst Decision
- NTGR Hold
- MLYS Strong Buy
- Analyst Count
- NTGR 1
- MLYS 2
- Target Price
- NTGR $13.00
- MLYS $30.00
- AVG Volume (30 Days)
- NTGR 298.9K
- MLYS 154.4K
- Earning Date
- NTGR 02-05-2025
- MLYS 11-11-2024
- Dividend Yield
- NTGR N/A
- MLYS N/A
- EPS Growth
- NTGR N/A
- MLYS N/A
- EPS
- NTGR 0.66
- MLYS N/A
- Revenue
- NTGR $680,014,000.00
- MLYS N/A
- Revenue This Year
- NTGR N/A
- MLYS N/A
- Revenue Next Year
- NTGR $6.07
- MLYS N/A
- P/E Ratio
- NTGR $38.92
- MLYS N/A
- Revenue Growth
- NTGR N/A
- MLYS N/A
- 52 Week Low
- NTGR $10.48
- MLYS $7.29
- 52 Week High
- NTGR $26.07
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- NTGR 80.04
- MLYS 44.20
- Support Level
- NTGR $25.06
- MLYS $11.61
- Resistance Level
- NTGR $25.80
- MLYS $12.44
- Average True Range (ATR)
- NTGR 0.96
- MLYS 0.74
- MACD
- NTGR 0.22
- MLYS -0.06
- Stochastic Oscillator
- NTGR 75.20
- MLYS 18.22
About NTGR NETGEAR Inc.
Netgear Inc is a provider of networking solutions. The reportable segments of the company are connected home, and Small and Medium Businesses (SMB). The Connected Home segment focuses on consumers and consists of high-performance, dependable, and easy-to-use 4G/5G mobile, Wi-Fi internet networking solutions, and smart devices such as Orbi Voice smart speakers and Meural digital canvas; and NETGEAR specializes in providing networking solutions for businesses, including wireless LAN, Pro AV applications for audio and video over Ethernet, security, and remote management.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.